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A B S T R A C T
Background: Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic
phase chronic myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies in-
clude dose adjustments, interrupting or discontinuing therapy, or switching to an alternative TKI.
Methods: This multicenter, single-arm, Phase IIIb study included CML-CP patients intolerant of, but responsive
to, first-line treatment with imatinib or dasatinib. All patients were switched to nilotinib 300mg bid for up to 24
months. The primary endpoint was achievement of MR4.5 (BCR-ABL transcript level of ≤0.0032% on the
International Scale) by 24 months.
Results: Twenty patients were enrolled in the study (16 imatinib-intolerant, 4 dasatinib-intolerant); which was
halted early because of low recruitment. After the switch to nilotinib 300mg bid, MR4.5 at any time point up to
month 24 was achieved in 10 of 20 patients (50%) in the full analysis set. Of the non-hematological adverse
events associated with intolerance to prior imatinib or dasatinib, 74% resolved within 12 weeks of switching to
nilotinib 300mg bid.
Conclusion: Nilotinib 300mg bid shows minimal cross intolerance in patients with CML-CP who have prior
toxicities to other TKIs and can lead to deep molecular responses.
1. Introduction
Guidelines recommend that the tyrosine kinase inhibitors (TKIs)
imatinib, nilotinib, and dasatinib be used for first-line treatment of
Philadelphia chromosome-positive (Ph+) chronic phase chronic mye-
loid leukemia (CML-CP) [1,2]. The goal of TKI therapy in CML-CP is to
achieve a major molecular response (MMR; a ≥3 log reduction in BCR-
ABL1 level corresponding to a BCR-ABL1 level of ≤0.1% on the
International Scale [IS]) within 12 months of starting treatment and
eventually a deep molecular response, as well as preventing progression
to accelerated phase CML (CML-AP) or blast phase CML (CML-BP)
[1–3]. The TKIs inhibit BCR-ABL1, a fusion protein that is a con-
stitutively active, oncogenic tyrosine kinase that plays a critical role in
CML pathogenesis. Measurement of BCR-ABL1 transcript levels using
real-time quantitative reverse transcriptase-polymerase chain reaction
(qRT-PCR) is the preferred method for monitoring the response to TKI
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therapy [1]. Regular monitoring of BCR-ABL1 levels should continue
after a response has been achieved in order to detect emerging re-
sistance or poor adherence [1,2].
Patients with newly diagnosed CML-CP who achieve a deep mole-
cular response with TKI therapy have improved long-term outcomes
[3–5], with MR4.5 (a ≥4.5 log reduction in BCR-ABL1 level corre-
sponding to a BCR-ABL1 level of ≤0.0032% IS) being a better predictor
of survival than complete cytogenetic response [5]. Achieving a deep
molecular response appears more likely with the second-generation
TKIs nilotinib or dasatinib than with the first-generation TKI imatinib
[6–12]. Current guidelines recommend lifelong TKI therapy for most
CML-CP patients [1,2]. However, recent data indicate that maintenance
of treatment-free remission may be possible in patients who achieve a
sustained deep molecular response [13]. Accordingly, discontinuation
of TKI therapy may be feasible in carefully selected patients who
achieve and maintain a deep molecular response [14,15].
The TKIs differ in terms of their adverse event (AE) profiles, possibly
reflecting differences in their molecular mechanisms of action and
target profiles [16]. For example, non-hematological AEs reported with
imatinib include gastrointestinal AEs, edema, rash, and fatigue [1];
those reported with dasatinib include pleural effusion [11,17] and
pulmonary arterial hypertension [18,19], ischemic heart disease (IHD)
and ischemic cerebrovascular events (ICVE) [20]; and those reported
with nilotinib include prolongation of the Fridericia-corrected QT
(QTcF) interval [21] and an increased risk of cardiovascular events
(including peripheral artery occlusive disease [PAOD], IHD and ICVE)
[6]. AEs may negatively impact health-related quality of life (HRQoL),
reduce treatment adherence, and lead to treatment interruption or
discontinuation, ultimately resulting in suboptimal outcomes [22–25].
Switching to an alternative TKI is an option in patients who are intol-
erant of first-line TKI therapy. This strategy is supported by post-hoc
data [26] from a Phase II trial [27,28] showing minimal cross intoler-
ance with nilotinib 400mg twice daily (bid) in CML patients who ex-
perienced imatinib-related AEs. In addition, the Phase II ENRICH study
showed that switching to nilotinib 300mg bid can mitigate chronic
low-grade non-hematological AEs associated with imatinib in CML-CP
patients [29].
In a number of countries, nilotinib 400mg bid is the approved do-
sage in patients with CML-CP and resistance or intolerance to prior TKI
therapy, whereas nilotinib 300mg bid is the approved dosage in newly
diagnosed CML-CP patients. Although some reimbursement agencies
may allow patients intolerant to TKIs to switch to nilotinib 300mg bid
(instead of the recommended 400mg bid dose in the second-line set-
ting), limited data are available to support the use of nilotinib 300mg
bid in these patients [29].
The aim of the current study, ENESTswift, was to assess the efficacy
and safety of switching to nilotinib 300mg bid in CML-CP patients who
were intolerant of first-line treatment with imatinib or dasatinib,
without having demonstrated treatment resistance, and who were yet to
achieve MR4.5.
2. Methods
2.1. Study design and population
ENESTswift was a multicenter, single-arm, Phase IIIb study evalu-
ating the safety and efficacy of nilotinib in CML-CP patients intolerant
of first-line treatment with imatinib or dasatinib and not in MR4.5
(NCT02108951). Eligibility criteria included age ≥18 years, an Eastern
Cooperative Oncology Group performance status of 0–2, Ph+ CML-CP
with BCR-ABL1 quantifiable by qRT-PCR, ≥3 months’ therapy with
imatinib or dasatinib or both, BCR-ABL1 level of< 1% IS during im-
atinib or dasatinib treatment, and experience of any non-hematological
AEs (any grade) that persisted for ≥1 month or recurred despite sup-
portive care. Patients requiring interruption of imatinib or dasatinib
(dose interruption of ≤28 consecutive days) because of non-
hematological AEs were also eligible. Key exclusion criteria were: prior
nilotinib; prior CML-AP, CML-BP, or allogeneic stem cell transplanta-
tion; documented MR4.5 at the screening visit; presence of a nilotinib-
resistant kinase mutation (mutation analysis not mandatory); known
impaired cardiac function; cytokine therapy within 4 weeks of study
entry. The study was conducted in accordance with the Declaration of
Helsinki, the protocol was approved by an independent ethics com-
mittee, and written informed consent was provided by patients.
2.2. Treatments
Prior to starting nilotinib, patients had an imatinib or dasatinib
washout period of ≥3 days. Patients then received oral nilotinib
300mg bid for up to 24 months. The nilotinib dose could be reduced to
450mg once daily in patients unable to tolerate the 300mg bid dose.
Treatment interruptions and dose reductions were allowed for man-
agement of AEs.
2.3. Study objectives
The primary endpoint was achievement of MR4.5 (BCR-ABL1
≤0.0032% IS) within 24 months of switching to nilotinib. MMR (BCR-
ABL1 ≤0.1% IS) and MR4.0 (a ≥4 log reduction in BCR-ABL1 level
corresponding to a BCR-ABL1 level of≤0.01% IS) were also assessed as
supportive endpoints. Secondary endpoints included molecular re-
sponse kinetics, improvement in AE grading from baseline to month 3
of nilotinib treatment, the safety profile of nilotinib 300mg bid, and the
change over time in HRQoL.
2.4. Efficacy assessments
BCR-ABL1 levels were determined using qRT-PCR testing of per-
ipheral blood [30], with samples collected pre-dose at day 1 (baseline),
at months 1, 2, and 3, and then every 3 months to month 24. The
percent ratio of BCR-ABL1 transcripts versus control gene (BCR) tran-
scripts converted to IS was calculated for each sample.
2.5. Safety assessments
Safety assessments included AEs (graded using Common
Terminology Criteria for Adverse Events [CTCAE] version 4.03), la-
boratory parameters, vital signs, and physical examination. The QTcF
interval was monitored using a standard 12-lead electrocardiogram.
AEs of special interest, including IHD, ICVE, and PAOD, were also
monitored.
Cardiovascular risk was assessed using Framingham Heart Study
calculators (http://www.framinghamheartstudy.org/risk-functions/
cardiovascular-disease/index.php), which provide an estimate of the
10-year general risk of cardiovascular disease (CVD) using baseline
total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C)
values. Data concerning other risk factors (eg diabetes mellitus, dysli-
pidemia, hypertension) were also collected, and risk factors were
managed as per local guidelines. The ankle-brachial index for each leg
was assessed at day 1 (baseline) and at months 12 and 24, with the
lowest value being automatically retained in the clinical database as
part of the data entry process.
2.6. Quality of life assessments
HRQoL and symptom burden were assessed using the MD Anderson
Symptom Inventory – Chronic Myeloid Leukemia (MDASI-CML) ques-
tionnaire [31].
2.7. Statistical analyses
The primary efficacy analysis was conducted in all enrolled patients.
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Safety was assessed in all enrolled patients who received at least one
dose of study drug and had at least one post-baseline safety assessment.
The planned enrollment target of 130 patients was expected to com-
prise 100 imatinib-intolerant patients and 30 dasatinib-intolerant pa-
tients.
The primary efficacy endpoint was considered as a binary response,
with the MR4.5 rate calculated as the ratio of the number of responders
(ie patients achieving MR4.5) to the sum of the number of responders
and non-responders. An overall 95% confidence interval (CI) was de-
termined using the Clopper-Pearson method.
Additional analyses were conducted for MMR and MR4.0, with the
MMR analysis conducted in the subgroup of patients not in MMR at
baseline (patients who were MMR, MR4.0, or MR4.5 were excluded)
and the MR4.0 analysis conducted in the subgroup of patients not in
MR4.0 at baseline (patients who were MR4.0 or MR4.5 were excluded).
The kinetics of the molecular response were assessed descriptively
by summarizing the BCR-ABL1 ratio each month for the first 3 months
of the study and then at 3-monthly intervals until 24 months.
MDASI-CML scores were summarized descriptively at baseline and
at 3-monthly intervals until 24 months.
Improvement in the severity of non-hematological AEs was ana-
lyzed in the safety set, with improvement defined as a reduction in the
CTCAE grading 3 months after switching to nilotinib or the resolution
of the AE in the 3 months after the switch.
3. Results
3.1. Study population
Twenty patients were screened and enrolled in the study, which was
halted early because of low recruitment. Four patients (20.0%) com-
pleted the study (completers were defined as patients who had a study
completion evaluation performed 30 days after the end of therapy), 14
patients (70.0%) were withdrawn because of early study termination (ie
study closure), one patient (5.0%) was lost to follow-up, and one pa-
tient (5.0%) withdrew their consent and discontinued the trial due to
planned pregnancy. Overall, no patient had 2 years of follow up, with a
maximum follow up duration of approximately 94 weeks seen in two
patients.
Baseline demographics are shown in Table 1. Sixteen patients had
received imatinib and four patients had received dasatinib as their most
recent TKI.
At baseline, eight patients (40.0%) were not in MMR, nine patients
(45.0%) were in MMR and one patient (5.0%) was in MR4.0. Two pa-
tients (10.0%) who were not in MR4.5 at screening, but were in MR4.5
at baseline, were therefore eligible for study entry (Table 1).
The median duration of nilotinib treatment was 415 days (range
128–658 days) and the median daily nilotinib dose (excluding zero dose
periods) was 600mg (range 279–600mg). Nilotinib dose reduction and
interruption occurred in one (5.0%) and two (10.0%) patients, re-
spectively. One patient (5.0%) discontinued nilotinib therapy because
of planned pregnancy, with no patients permanently discontinuing ni-
lotinib because of AEs.
3.2. Efficacy
MR4.5 between baseline and month 3 of nilotinib treatment was
seen in 7 of 20 patients (35.0%; 95% CI 15.4, 59.2); at baseline, one of
these patients was not in MMR, three were in MMR, one was in MR4.0,
and two were in MR4.5. MR4.5 at any time point up to month 24
(primary endpoint) was seen in 10 of 20 patients (50.0%; 95% CI 27.2,
72.8). All 10 patients had achieved MR4.5 by month 12 of the study;
the duration of prior TKI exposure in these patients versus those not
achieving MR4.5 is presented in the Supplementary material. Molecular
response rates over time are shown in Fig. 1.
A sensitivity analysis excluding the two patients in MR4.5 at base-
line found that MR4.5 between baseline and month 3 of nilotinib
treatment was achieved in 5 of 18 patients (27.8%; 95% CI 9.7, 53.5)
and MR4.5 at any time point up to month 24 was achieved in 8 of 18
patients (44.4%; 95% CI 21.5, 69.2).
At any time point up to month 12, MMR was achieved in 6 of 8
patients not in MMR at baseline (75.0%; 95% CI 34.9, 96.8) and MR4.0
was achieved in 11 of 17 patients not in MR4.0 at baseline (64.7%; 95%
CI 38.3, 85.8). At any time point up to month 24, MMR was achieved in
6 of 8 patients (75.0%; 95% CI 34.9, 96.8) and MR4.0 was achieved in
12 of 17 patients (70.6%; 95% CI 44.0, 89.7). The lowest BCR-ABL
levels seen in the two patients not achieving MMR at any time during
the study were 2.200% at week 24 and 0.180% at week 48, respec-
tively.
Median BCR-ABL1 values were 0.068% IS at baseline and 0.006% IS
at week 96/end of study (EOS) (Fig. 2).
The proportion of patients achieving a 1-log reduction in BCR-ABL1
levels over time is shown in Fig. 3. Among the subgroup of patients not
in MR4.0 or MR4.5 at baseline, a 1-log reduction in BCR-ABL1 levels
occurred as early as week 8 in three patients, with an additional five
patients achieving a 1-log reduction in BCR-ABL1 levels by week 12.
There were no reports of death during the study, or withdrawal
because of progression to CML-AP or CML-BP, or treatment failure.
3.3. Overall safety profile
In total, 61 non-hematological AEs were reported at baseline across
the 20 patients in the safety set who had been receiving prior TKI
therapy (AEs had persisted for ≥1 month or recurred despite suppor-
tive care). The vast majority of these AEs were Grade 1 or 2, and there
were no Grade 4 AEs (Table 2 and Supplementary Table 1). The most
commonly reported AEs were nausea and fatigue (Table 2). The change
over time in pre-existing AEs is shown in Supplementary Table 2 and
Fig. 4. Twelve weeks following the switch from imatinib or dasatinib to
nilotinib, 73.8% of the AEs had resolved (Table 2).
Subgroup analysis revealed that after 12 weeks of nilotinib therapy,
35 of the 50 (70%) AEs reported during prior imatinib therapy and 10
of the 11 (91%) AEs reported during prior dasatinib therapy had re-
solved.
All 20 patients experienced at least one treatment-emergent AE
(TEAE) during nilotinib therapy (Table 3). The majority of non-serious
TEAEs were of grade 1 (113 of 148; 76.4%) or grade 2 (32 of 148;
21.6%) intensity. Of the remaining non-serious TEAEs, two were of
Table 1
Summary of patient demographics and baseline characteristics.
N= 20
Age, years
Mean (SD) 53.9 (15.1)




Duration of prior TKI therapy, months
Mean (SD) 51.0 (44.14)
Median (range) 42.5 (2–154)
Most recent TKI, n (%)
Imatinib 16 (80.0)
Dasatinib 4 (20.0)
BCR-ABL1 response at baseline, n (%)




MMR, major molecular response; SD, standard deviation; TKI, tyrosine
kinase inhibitor.
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grade 3 intensity (type 2 diabetes and osteoarthritis) and one (hyper-
uricemia) was of grade 4 intensity, although this event was not con-
sidered to be related to nilotinib and was not classified as serious. One
serious TEAE (pneumonia) was reported during the study, but was not
considered to be related to nilotinib.
The most commonly reported treatment-related AEs included fa-
tigue and constipation (Table 3).
Five patients (25%) had grade 1 or 2 elevations in liver enzymes,
creatinine phosphokinase, lipase, or amylase. No patient experienced
hematological AEs during the study.
A change from baseline in the QTcF interval of> 60ms was re-
ported in one patient; it was considered treatment related and nilotinib
was temporarily interrupted.
3.4. Cardiovascular risk assessment and monitoring
Regarding baseline Framingham index estimates, three patients
were not evaluated because of missing lipid values. Of the remaining
patients, 13, 1, and 3 patients were at low (Framingham estimate<
10%), moderate (10–15%), and high (> 15%) risk of CVD, respectively
(see the Supplementary material).
According to the American Heart Association, the goal is to keep the
TC:HDL-C ratio (an indicator of cardiovascular risk [32])< 5:1, with a
ratio of< 3.5:1 considered an ideal target [33]. Among patients with
baseline data for TC and HDL-C (n=16), 81% of patients had a
TC:HDL-C ratio of< 5:1 and 56% of patients had a TC:HDL-C ratio
of< 3.5:1 before starting nilotinib. At EOS, TC:HDL-C ratios remained
within the target ranges in the majority of patients (87% of patients had
a TC:HDL-C ratio of< 5:1 and 53% had a TC:HDL-C ratio of< 3.5:1).
None of the seven patients who had low-density lipoprotein cho-
lesterol (LDL-C) to target at baseline were at target at EOS, and of six
patients with LDL-C not to target at baseline, five were still not to target
at EOS, with data from the sixth patient missing.
At baseline before starting nilotinib, all 17 evaluable patients had
glycated hemoglobin (HbA1c) levels within the target range (100%),
and 89% of patients also had fasting plasma glucose (FPG) levels within
the target range. At EOS, the majority of patients remained within the
target ranges for HbA1c and FPG (92% and 80%, respectively).
There were no reports of IHD, ICVE, or PAOD.
3.5. Quality of life
Changes from baseline to week 96/EOS in mean total scores for
symptom severity (part 1 core and CML questions) and interference of
symptoms on daily life (part 2 core questions) are shown in Table 4.
4. Discussion
Inadequate management of AEs in patients receiving TKI therapy
may lead to reduced treatment adherence and poor outcomes, including
Fig. 1. Proportion of patients achieving a molecular response over time.
*Two patients did not have BCR-ABL results at week 96/EOS (EOS was defined as the early termination visit).
Bsl, baseline; EOS, end of study; MMR, major molecular response; Scr, screening.
Fig. 2. BCR-ABL1 levels over time.
Boxes represent the inter-quartile range (IQR, 25th and 75th percentiles), horizontal bars represent median values, whiskers represent 1.5× IQR, diamonds represent mean values, and
circles represent individual values outside of 1.5× IQR. Values > 2 are not shown.
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suboptimal molecular responses [23,34,35]. Most AEs associated with
TKI therapy can be managed using symptomatic treatment or dose re-
duction [22]. However, some patients experience AEs that do not re-
spond to these measures and these patients are regarded as TKI-intol-
erant [22]. Managing TKI intolerance by discontinuing or interrupting
treatment may lead to unfavorable outcomes, and a more appropriate
strategy may be to switch to an alternative TKI.
In ENESTswift, switching to nilotinib 300mg bid because of intol-
erance to prior imatinib or dasatinib appeared to be an effective and
well-tolerated strategy in most patients with CML-CP. It should be
noted that early termination of the study has not allowed for a robust
analysis. One possible reason for the slow accrual is that because the
Australian Pharmaceutical Benefits Scheme permits patients to switch
from imatinib to a second-generation TKI, switching may be occurring
without patients being entered into a clinical study.
Despite low patient recruitment, the findings of ENESTswift are
important considering that data concerning the efficacy and tolerability
of nilotinib 300mg bid in TKI-intolerant patients with CML-CP are
limited [29]. The results of ENESTswift are particularly relevant for
countries where reimbursement or access for TKI switching because of
intolerance during first-line therapy is based on a nilotinib dosage of
300mg bid.
In terms of the molecular response at baseline, the majority of pa-
tients were in MMR, with only one patient in MR4.0 and two patients in
MR4.5. Within 24 months of switching to nilotinib 300mg bid, MR4.5
was achieved in 10 of 20 patients overall and in 8 of 18 patients when
the two patients in MR4.5 at baseline were excluded.
Following the switch to nilotinib, a rapid decrease in BCR-ABL1
levels was apparent in the subgroup of patients with higher BCR-ABL1
levels at baseline (ie those who were not in MR4.0 or MR4.5). Overall, a
1-log reduction in BCR-ABL1 levels was seen in 45.0% of patients by
month 3 of nilotinib treatment.
Approximately three-quarters of non-hematological AEs associated
with intolerance to prior imatinib or dasatinib therapy resolved within
12 weeks of switching to nilotinib 300mg bid. These results support the
findings of earlier studies indicating that cross intolerance between
nilotinib and imatinib is infrequent [27,29].
The safety profile of nilotinib in ENESTswift was generally con-
sistent with that seen in previous studies [6–9]. The vast majority of
TEAEs were of mild-to-moderate severity, with the most commonly
reported treatment-related AEs being fatigue and constipation. No
cardiovascular safety concerns emerged during the study. Guidelines
recommend that patients should be evaluated for pre-existing PAOD
and vascular risk factors before they start, and during, nilotinib therapy
[1].
4.1. Conclusions
This study supports a strategy of switching to nilotinib 300mg bid
in CML-CP patients who do not tolerate imatinib or dasatinib in the
first-line setting. Given the small patient numbers, further study in a
larger population is indicated.
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MedDRA, Medical Dictionary for Regulatory Activities.
Table 4
Change over time in MDASI-CML scores assessing symptom severity and interference of
symptoms on daily life in patients receiving nilotinib.
Time point Number of
patients*
Mean (SD) total
score for part 1
core questions
Mean (SD) total
score for part 1
CML questions
Mean (SD) total
score for part 2
core questions
Baseline 20/20/20 26.6 (23.88) 14.3 (11.71) 12.4 (14.17)
Week 12 19/18/18 22.7 (20.31) 7.4 (9.34) 7.8 (11.92)
Week 24 16/16/16 20.7 (18.08) 10.1 (11.19) 8.2 (12.20)
Week 36 15/14/14 19.1 (15.78) 8.9 (8.57) 6.1 (6.27)
Week 48 12/12/12 20.4 (16.57) 7.8 (9.00) 7.6 (10.53)
Week 60 7/7/7 24.0 (34.09) 7.7 (11.69) 2.9 (7.56)
Week 72 5/5/5 19.6 (29.52) 4.2 (6.72) 9.6 (21.47)
Week 84 3/3/3 32.7 (41.24) 12.3 (16.29) 13.3 (23.09)
Week 96/EOS† 19/19/18 17.5 (20.44) 7.8 (11.49) 9.9 (15.59)
EOS, end of study; MDASI-CML, MD Anderson Symptom Inventory – Chronic Myeloid
Leukemia; SD standard deviation.
MDASI-CML assesses symptom severity (13 core items [part 1 core questions] and seven
CML-specific items [part 1 CML questions] scored from 0 [not present] to 10 [as bad as
imagined]) and interference of symptoms on daily life (six core items [part 2 core
questions] scored from 0 [did not interfere] to 10 [interfered completely]).
* Number of evaluable patients for part 1 core questions/part 1 CML questions/part 2
core questions.
† Week 96 includes EOS results for patients who did not complete the study.
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